{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:42:22Z","timestamp":1740109342056,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We evaluated the medication selection and clinical characteristics of rheumatoid arthritis patients who started treatment with\/without methotrexate (MTX) (using biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors instead) in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using a Japanese hospital-based administrative claims database, rheumatoid arthritis patients who received treatment [abatacept (ABA), interleukin-6 receptor inhibitor, tumor necrosis factor inhibitor, or Janus kinase inhibitor] between 1 January 2015 and 31 December 2019 were enrolled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 19,301 patients were included (10,530 receiving MTX; 8771 not receiving MTX within 60\u2009days of the first treatment). Mean ages at diagnosis were 60.7 and 65.9\u2009years in the MTX and non-MTX groups, respectively (P\u2009&amp;lt;\u2009.0001). The non-MTX group had higher proportions of patients with Charlson Comorbidity Index \u22651 (P\u2009&amp;lt;\u2009.0001) and higher comorbidity rates. ABA was the most frequently used drug among patients with infectious\/parasitic, circulatory, and respiratory diseases at baseline. Interleukin-6 receptor inhibitor had the highest use rate among patients with neoplasms; blood, gastrointestinal, and genitourinary diseases; and abnormal clinical\/laboratory findings. ABA had the highest persistence probability from 6\u2009months onward.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MTX is used less frequently among older Japanese rheumatoid arthritis patients or those with comorbidities. In such patients, ABA is the most frequently used drug, followed by interleukin-6 receptor inhibitor, when MTX is not used at treatment start.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae021","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:40:58Z","timestamp":1709811658000},"page":"900-909","source":"Crossref","is-referenced-by-count":0,"title":["Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-0333","authenticated-orcid":false,"given":"Naohisa","family":"Miyakawa","sequence":"first","affiliation":[{"name":"Japan Medical, Innovative Medicine, Bristol Myers Squibb K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuki","family":"Tsuritani","sequence":"additional","affiliation":[{"name":"Japan Medical, Innovative Medicine, Bristol Myers Squibb K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Casaes","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Real-World-Data Analytics, Bristol Myers Squibb , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2024101507120906600_R1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024101507120906600_R2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2024101507120906600_R3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2024101507120906600_R4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024101507120906600_R5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024101507120906600_R6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024101507120906600_R7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2165\/00002512-199609060-00008","article-title":"Use of methotrexate in older patients. A risk-benefit assessment","volume":"9","author":"Tett","year":"1996","journal-title":"Drugs Aging"},{"key":"2024101507120906600_R8","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","author":"Rheumatoid Arthritis Clinical Trial Archive Group.","year":"1995","journal-title":"J Rheumatol"},{"key":"2024101507120906600_R9","first-page":"973","article-title":"The effect of age on methotrexate efficacy and toxicity","volume":"18","author":"Wolfe","year":"1991","journal-title":"J Rheumatol"},{"key":"2024101507120906600_R10","article-title":"Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment","volume":"6","author":"Fragoulis","year":"2019","journal-title":"Front Med Lausanne"},{"key":"2024101507120906600_R11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis\u2014secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"author":"Medical Data Vision","article-title":"MDV Latest Medical Data Map","key":"2024101507120906600_R12"},{"author":"Ministry of Health, Labour and Welfare, Japan.","article-title":"Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects","key":"2024101507120906600_R13"},{"key":"2024101507120906600_R14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2024101507120906600_R15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2024101507120906600_R16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024101507120906600_R17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024101507120906600_R18","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024101507120906600_R19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s40744-021-00356-2","article-title":"Abatacept is efficacious in the treatment of older patients with csDMARD-refractory rheumatoid arthritis: a prospective, multicenter, observational study","volume":"8","author":"Muraoka","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024101507120906600_R20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274775","article-title":"Comparing the effectiveness and safety of abatacept and tocilizumab in elderly patients with rheumatoid arthritis","volume":"17","author":"Temmoku","year":"2022","journal-title":"PLoS One"},{"key":"2024101507120906600_R21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"2024101507120906600_R22","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223698","article-title":"The role of IL-6 in cancer cell invasiveness and metastasis\u2014overview and therapeutic opportunities","volume":"11","author":"Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"key":"2024101507120906600_R23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2024101507120906600_R24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14740338.2016.1238458","article-title":"Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Bonovas","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2024101507120906600_R25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","article-title":"Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies","volume":"53","author":"Micic","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"2024101507120906600_R26","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"51","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024101507120906600_R27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"author":"Center for Drug Evaluation and Research","article-title":"Drug Safety Information for Healthcare Professionals \u2013 Questions and Answers \u2013 TNF Blockers 8\/25\/2009","key":"2024101507120906600_R28"},{"key":"2024101507120906600_R29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/mr\/roac025","article-title":"Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"33","author":"Terabe","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024101507120906600_R30","article-title":"History of the development of corticosteroid therapy","volume":"29","author":"Benedek","year":"2011","journal-title":"Clin Exp Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae021\/57212694\/roae021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/900\/59755467\/roae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/900\/59755467\/roae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T07:13:30Z","timestamp":1728976410000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/5\/900\/7623679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae021","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"type":"print","value":"1439-7595"},{"type":"electronic","value":"1439-7609"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,7]]}}}